280 related articles for article (PubMed ID: 26973310)
1. Bedaquiline plus delamanid for XDR tuberculosis.
Lachâtre M; Rioux C; Le Dû D; Fréchet-Jachym M; Veziris N; Bouvet E; Yazdanpanah Y
Lancet Infect Dis; 2016 Mar; 16(3):294. PubMed ID: 26973310
[No Abstract] [Full Text] [Related]
2. Compassionate and optimum use of new tuberculosis drugs.
Matteelli A; D'Ambrosio L; Centis R; Tadolini M; Migliori GB
Lancet Infect Dis; 2015 Oct; 15(10):1131-1132. PubMed ID: 26461941
[No Abstract] [Full Text] [Related]
3. Compassionate and optimum use of new tuberculosis drugs.
Reed C; Mason L; Cox H; Seaworth B; Lessem E; Furin J
Lancet Infect Dis; 2015 Oct; 15(10):1131. PubMed ID: 26461942
[No Abstract] [Full Text] [Related]
4. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
[TBL] [Abstract][Full Text] [Related]
5. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
Tadolini M; Lingtsang RD; Tiberi S; Enwerem M; D'Ambrosio L; Sadutshang TD; Centis R; Migliori GB
Eur Respir J; 2016 Sep; 48(3):935-8. PubMed ID: 27288039
[TBL] [Abstract][Full Text] [Related]
6. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
[TBL] [Abstract][Full Text] [Related]
7. Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc?
Shah I; Gandhi S; Shetty NS
Pediatr Infect Dis J; 2020 Jun; 39(6):512-513. PubMed ID: 32032176
[TBL] [Abstract][Full Text] [Related]
8. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
Wolfson LJ; Gibbert J; Wirth D; Diel R
Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
[No Abstract] [Full Text] [Related]
10. Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Lessem E; Cox V; Furin J
Lancet Respir Med; 2017 Oct; 5(10):772-774. PubMed ID: 28887015
[No Abstract] [Full Text] [Related]
11. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
Pontali E; Sotgiu G; Tiberi S; Tadolini M; Visca D; D'Ambrosio L; Centis R; Spanevello A; Migliori GB
Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29903862
[No Abstract] [Full Text] [Related]
13. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
[No Abstract] [Full Text] [Related]
14. Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis - United States, 2017.
Lardizabal AA; Khan AN; Bamrah Morris S; Goswami ND
MMWR Morb Mortal Wkly Rep; 2018 Sep; 67(35):996-997. PubMed ID: 30188880
[No Abstract] [Full Text] [Related]
15. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.
Bloemberg GV; Keller PM; Stucki D; Trauner A; Borrell S; Latshang T; Coscolla M; Rothe T; Hömke R; Ritter C; Feldmann J; Schulthess B; Gagneux S; Böttger EC
N Engl J Med; 2015 Nov; 373(20):1986-8. PubMed ID: 26559594
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
Millard J; Rimmer S; Nimmo C; O'Donnell M
Emerg Infect Dis; 2023 May; 29(5):1081-1084. PubMed ID: 37081529
[TBL] [Abstract][Full Text] [Related]
17. Barriers to new drug development in respiratory disease.
Brigden G; du Cros P; Wong S
Eur Respir J; 2016 Jan; 47(1):356-7. PubMed ID: 26721975
[No Abstract] [Full Text] [Related]
18. Management of drug resistantTB in patients with HIV co-infection.
Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
[TBL] [Abstract][Full Text] [Related]
19. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
20. Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.
Hafkin J; Hittel N; Martin A; Gupta R
Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30361253
[No Abstract] [Full Text] [Related]
[Next] [New Search]